BAD VILBEL, Germany & LONDON, March 31 — CapVest Partners LLP (“CapVest”), a leading global investment firm, today announces the completion of its acquisition of the majority stake in STADA Arzneimittel AG (“STADA” or the “Company”), a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty Pharmaceuticals.
Building on strong 2025 results, the completion of the transaction will allow the CapVest and STADA teams to jointly progress their ambitious plans to accelerate the growth of the company globally and deploying capital towards pursuing organic growth and new strategic acquisitions.
Currently employing close to 12,000 people worldwide, STADA is a leading, diversified global healthcare platform with a strategic focus on Consumer Healthcare, Generics and Specialty Pharmaceuticals. The Company recently announced record revenues of €4.3 billion, a 6% increase on the previous year, and all-time high adjusted EBITDA of €961 million in the financial year.
Peter Goldschmidt, Chief Executive Officer of STADA, commented: “We are delighted the transaction has now completed. CapVest’s deep knowledge and experience in healthcare, as well as their commitment to supporting our continued growth ambitions, will be a great asset as we look to realise our exciting plans for the business.”
Matt Fargie, Partner at CapVest, said: “While we have worked to complete this transaction, the STADA team has continued to demonstrate strong growth across key regions and consumer healthcare, generics, biosimilars and innovative medicines. We are excited to now be in a position to work actively with the team to deliver our ambitious shared plans for the business.”
The transaction was completed having satisfied all regulatory approvals and other customary closing conditions.
